Tolosa-Hunt syndrome presents as painful ophthalmoplegia — severe orbital or periorbital pain combined with cranial nerve paresis causing impaired eye movement. The clinical priority is rapid, effective intervention to address both the pain and the motor deficit.
Corticosteroid therapy is the established cornerstone of first-line management for Tolosa-Hunt syndrome. The complete structured regimen — covering agent selection, administration details, and sequencing — is reserved in the full protocol.
The primary targets are resolution of orbital and periorbital pain and recovery from ophthalmoplegia (paresis). With adequate corticosteroid therapy, a meaningful clinical response is expected within 48 hours.
DOI: 10.4236/ym.2020.42014
Generally corticosteroid therapy such as prednisolone (PSL), methylprednisolone (mPSL) and dexamethasone, given either orally or intravenously for THS results in climactic improvement in pain which is usually apparent in a few days, notwithstanding the fact that corticosteroids are the cornerstone of treatment for THS, there are controversies concerning effective course, route of administration, optimal dosage, period of therapy and treatment in special groups such as pregnant women and children, a case with fastest recovery has been portrayed in a young male with retro obital pain and ocular motilities resolving in 12 hours of the first high dose IV mPSL of 500 mg BID for 3 days and nearly absolute normalization in 4 days and kept on 7 days daily maintenance dose of prednisone 60 mg.
Finally, Lawton Smith and David Taxdal in 1966 added five cases on top of the cases reported by Dr. Tolosa and Hunt et al. to initiate the use of the term THS as the painful ophthalmoplegia associated with CN paralysis that responded to corticosteroid treatment in 48 hours.
The pain and paresis should eventually resolute with adequate corticosteroids therapy and shouldn't be outshined by other ICHD-3 diagnoses.